Navigation Links
DURECT Provides Update on CHRONOGESIC(R) Research Program
Date:4/7/2008

CUPERTINO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Endo Pharmaceuticals has stated that it intends to return the rights to CHRONOGESIC(R) licensed from DURECT Corporation for the U.S. and Canada. CHRONOGESIC is a product candidate consisting of a sufentanil containing implantable device intended for the treatment of moderate-to-severe chronic pain. As a result, the Development, Commercialization and Supply License Agreement between Endo and DURECT entered into in November 2002 will terminate. This return of CHRONOGESIC rights has no effect on DURECT and Endo's collaboration with respect to the sufentanil transdermal patch (TRANSDUR(TM)-Sufentanil) licensed by Endo from DURECT for the U.S. and Canada.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies focused on treating chronic and episodic diseases and conditions. The Company currently has multiple late-stage pharmaceutical products in development initially focused on significant unmet medical needs in pain management, with a number of research programs underway in a variety of other therapeutic areas. For more information, please visit http://www.durect.com.

NOTE: CHRONOGESIC(R) and TRANSDUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. TRANSDUR-Sufentanil is a drug candidate under development and has not been submitted or approved for commercialization by the US Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statement in this press release regarding DURECT's emergence as a specialty pharmaceutical company and DURECT's product candidates are forward- looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, DURECT's (and that of its third party collaborators where applicable) abilities to obtain approvals from regulatory agencies with respect to its development activities and product candidates, design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the product candidates, consummate collaborative agreements relating to our product candidates and technologies, manufacture and commercialize the product candidates, obtain marketplace acceptance of the product candidates and manage and obtain capital to fund its growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-K dated March 13, 2008 under the heading "Risk Factors."


'/>"/>
SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT to Participate in Cowen Annual Healthcare Conference
2. DURECT to Participate in Susquehanna Financial Healthcare Conference
3. DURECT to Present at BIO CEO Investor Conference 2008
4. DURECT to Present at 2007 BIO Investor Forum
5. DURECT to Present at UBS Global Life Sciences Conference
6. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
7. LIFE Provides Medical Books and Surgical Supplies to Iraq
8. Comfort C(R) Provides Significantly Higher Absorption Than Other Leading Brand
9. Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating
10. Flagship Global Health Provides 2008 Financial Guidance
11. MedPage Today(R) Provides First-Time Live Video Coverage of Medical Meeting Press Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... 2017 , ... The Women’s Choice Award, a growing platform that gives a ... Women’s Choice Award. The identification by women of an effective new migraine relief ... are women. In a survey taken by the Women’s Choice Award organization, nine out ...
(Date:8/22/2017)... ... August 22, 2017 , ... GeBBS ... recently the availability of a new professional fee E/M leveling calculator tool. The ... to the healthcare industry. E/M coding is complex which supports the need for ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... of child abuse and neglect, and the struggles faced while hoping for a ... creation of published author, Judy Von Bernewitz, who spent 13 years working with ...
(Date:8/22/2017)... ... ... “Call Of Spiritual Duty”: a revelation in an era defined by intentional confusion. ... up on the streets of North Visalia, California, Carlos Lizarde quickly became familiar with ... to his life, he noticed immediately that opportunities and blessings began to shift in ...
(Date:8/21/2017)... , ... August 21, 2017 , ... ... addition of two plastic surgery fellows for academic year 2017-2018, Christina M. Busuito, ... who have successfully completed residency in Plastic and Reconstructive Surgery. The candidate ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... 2017  Life Flight Network and PeaceHealth Oregon Network announced ... care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Life Flight Network work collaboratively to move patients who require ... a time sensitive emergency exists. ...
(Date:7/31/2017)... Tru-D SmartUVC robots have arrived at Brian Allgood Army Community ... for "Total Room Ultraviolet Disinfection," is a 5-foot-5 germ-killing robot that is ... cleans the area with traditional cleaning protocols. ... Tru-D fights germs at Army hospitals ... "Although the BAACH has a very low infection rate, below national ...
(Date:7/27/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... 30, 2017.  The Company reported second quarter net sales ... prior year period, and an increase of 2.1% on ... of contribution from the LDR Holding Corporation acquisition, second ... of 2016, or 0.3% on a constant currency basis. ...
Breaking Medicine Technology: